Anupam Rasayan India Limited Reports Q3FY23 Results.
Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended December 31, 2022.
Consolidated Financial Highlights for Quarter Ended December 31st , 2022:
Operating Revenues at ₹3,827 million in Q3FY23 as compared to ₹2,662 million in Q3FY22 – growth of 44% Y-o-Y.
Total Revenues at ₹3,888 million in Q3FY23 as compared to ₹2,711 million in Q3FY22 – growth of 43% Y-o-Y.
EBITDA (incl. other revenue) at ₹1080 million in Q3FY23 as compared to ₹800 million in Q3FY22 – growth of 35% Y-o-Y.
Profit After Tax at ₹544 million in Q3FY23 as compared to ₹379 million in Q3FY22 – growth of 44% Y-o-Y
Anand Desai, Managing Director of Anupam Rasayan, commented, “I am pleased to inform you that despite unavailability of the certain capacities during the quarter, we were able to deliver growth on YoY basis. If you adjust the deferred revenue due to capacity constrain then our growth would have been around 25% during the quarter.
I am delighted to share that we have received approval to restart the plant from the GPCB and other regulatory authorities after following all the regulatory and safety compliances. This shows our unwavering focus on compliance and maintaining high levels of manufacturing and safety standards, which has helped us get the closure order lifted within a shorter time span.
We continue to strengthen our business development team as we have a strong pipeline of products to launch in coming quarters. Our customer interactions remain very encouraging, and we have specifically seen strong interest from various customers on the fluorination side.
Overall, our strong pipeline of products, availability of the capacity, advance stage discussion with various clients along with capex which is moving ahead of the plan makes me confident of delivering strong and sustainable growth in coming quarters and years.”
About Author
